Figure 1 | British Journal of Cancer

Figure 1

From: Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)

Figure 1

Kaplan–Meier estimates of recurrence-free survival in patients with high-risk GIST. Historical controls (black) were only treated with R0 resection (mean follow-up 36 months, range 2–151 months), while the consecutive series of patients (mean follow-up 40 months, range 18–62 months) had adjuvant imatinib (400 mg day−1) for 1 year after radical surgery (red). In the latter group only one patient has developed recurrence.

Back to article page